Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Socioeconomic considerations in erectile dysfunction treatment.

R Shabsigh1

  • 1Department of Urology, Columbia University, New York, New York, USA. RS66@columbia.edu

The Urologic Clinics of North America
|June 14, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician.

International journal of clinical practice·2013
Same author

Are men shortchanged on health? Perspective on life expectancy, morbidity, and mortality in men and women in the United States.

International journal of clinical practice·2010
Same author

Are men shortchanged on health? Perspective on health care utilization and health risk behavior in men and women in the United States.

International journal of clinical practice·2010
Same author

Sexual function in health and disease.

Postgraduate medicine·2009
Same author

Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success.

International journal of impotence research·2009
Same author

Daily patterns of sexual intercourse attempts by men with erectile dysfunction treated with tadalafil: influence of age and marital status.

International journal of impotence research·2009
Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026
Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026
Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
See all related articles

Sildenafil has revolutionized erectile dysfunction treatment, expanding the patient population. This analysis explores the economic impacts of new erectile dysfunction therapies.

Area of Science:

  • Urology
  • Health Economics
  • Pharmacoeconomics

Background:

  • Erectile dysfunction (ED) significantly impacts patient quality of life and incurs healthcare costs.
  • The advent of oral phosphodiesterase type 5 inhibitors, notably sildenafil, has transformed ED management.
  • Previous treatment paradigms for ED were often invasive or less effective, limiting patient access and adherence.

Purpose of the Study:

  • To analyze the socioeconomic shifts in erectile dysfunction care following the introduction of oral therapies.
  • To provide a descriptive and analytic economic assessment of the implications of ED treatment.
  • To understand the evolving patient demographics and treatment-seeking behaviors for ED.

Main Methods:

  • Review of healthcare utilization and cost data related to ED treatment.

Related Experiment Videos

  • Analysis of patient demographic trends before and after the widespread adoption of oral ED medications.
  • Economic modeling to assess the cost-effectiveness and societal impact of ED therapies.

    • Main Results:

    • Significant expansion in the patient population seeking ED treatment since the introduction of sildenafil.
    • Shift in treatment preferences towards oral pharmacotherapy due to efficacy and convenience.
    • Increased healthcare resource utilization associated with a broader ED patient base.

    Conclusions:

    • Oral ED therapies like sildenafil have dramatically altered the socioeconomic landscape of erectile dysfunction.
    • The expanded patient pool presents both opportunities for improved health outcomes and challenges for healthcare resource allocation.
    • Further pharmacoeconomic research is warranted to optimize treatment strategies and manage the economic burden of ED.